Get started
GSK PLC CEDEAR EACH REPR 1/4 ADRGSK PLC CEDEAR EACH REPR 1/4 ADRGSK PLC CEDEAR EACH REPR 1/4 ADR

GSK PLC CEDEAR EACH REPR 1/4 ADR

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

GSK chart


Full chart

Key facts today

GSK's Advair and Anoro Ellipta are part of the treatment options for chronic obstructive pulmonary disease (COPD), while mepolizumab is noted as a mid-stage drug in development for COPD management.
On 13 November 2024, GSK PLC provided a block listing interim review as part of their six-monthly return.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪71.05 T‬ ARS
Dividend yield (indicated)
3.79%
Price to earnings Ratio (TTM)
33.621
Basic EPS (TTM)
311.325 ARS
Net income (FY)
‪1.80 T‬ ARS
Revenue (FY)
‪11.10 T‬ ARS
Shares float
—
Beta (1Y)
0.29

About GSK PLC ORD GBP0.3125


Sector
Health Technology
CEO
Emma N. Walmsley
Headquarters
London
Website
gsk.com
ISIN
ARDEUT110483
FIGI
BBG000CZGKJ6
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GSK news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

GSK highest yielding bonds


G
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45
Yield to maturity
5.57%
Maturity date
Dec 18, 2045
G
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042
Yield to maturity
5.38%
Maturity date
Apr 10, 2042
G
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
5.37%
Maturity date
May 15, 2038
G
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39
Yield to maturity
5.34%
Maturity date
Mar 9, 2039
G
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.32%
Maturity date
Mar 18, 2043
G
XS217060907
GLAXOSM.CAP. MTN 20/35MTN
Yield to maturity
5.00%
Maturity date
May 12, 2035
G
AG99
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033
Yield to maturity
4.82%
Maturity date
Dec 19, 2033
G
72WI
GLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/2034
Yield to maturity
4.69%
Maturity date
Apr 15, 2034
G
US377373AH8
GLAXOSM.CAP. 19/29
Yield to maturity
4.64%
Maturity date
Jun 1, 2029
G
US377372AN7
GLAXOSMITHKLINE CAP.18/28
Yield to maturity
4.58%
Maturity date
May 15, 2028
G
XS217060184
GLAXOSM.CAP. MTN 20/28MTN
Yield to maturity
4.50%
Maturity date
Oct 12, 2028

Explore more bonds 

Sparks


Curated watchlists where GSK is featured.

See all sparks